Pinnacle Medicines raised $89 million in a series B to advance its oral peptide programs, including next steps across its chemistry and clinical pipeline. The round brings Pinnacle’s total capital raised to $134 million and was co-led by LAV and Foresite Capital, with Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and existing investors also participating. The financing supports continued execution for the company’s oral peptide platform, built to expand on the demonstrated feasibility of peptide-based GLP-1-style therapies. Pinnacle’s fundraising also reflects sustained investor interest in non-injectable formats for chronic metabolic and other indications, where dosing convenience can materially affect adherence.